This bill is short and prescriptive: it directs that the Secretary of Health and Human Services may not implement the ‘‘Wasteful and Inappropriate Services Reduction (WISeR) Model’’ described in the Federal Register notice (90 Fed. Reg. 28749 (July 1, 2025)) or any substantially similar model under the Medicare program.
In practical terms, it forecloses CMS from using the particular prior‑authorization approach set out in that notice as a tool within Medicare.
The measure matters because it substitutes a blunt statutory prohibition for administrative judgment. CMS has been using demonstration and model authority to test utilization management tools such as targeted prior authorization; this bill would remove one such tool from the agency’s toolkit entirely and raise questions about how narrowly or broadly HHS may pursue similar approaches going forward.
At a Glance
What It Does
The bill prohibits the HHS Secretary from implementing the WISeR model described in the July 1, 2025 Federal Register notice and bars any ‘‘substantially similar’’ model from being implemented under Medicare. It is a single substantive restraint with no carveouts, transition rules, or funding directives.
Who It Affects
The ban affects the Centers for Medicare & Medicaid Services (CMS) and its contractors, Medicare beneficiaries who could be subject to prior‑authorization reviews, and clinicians and suppliers whose services the WISeR notice targeted. Vendors and third‑party prior‑authorization platforms also face an immediate loss of a potential federal deployment market.
Why It Matters
The statute replaces an administrative pilot with a legislative prohibition, limiting CMS’s ability to test or deploy prior‑authorization mechanisms aimed at reducing low‑value or wasteful services. That has implications for program integrity efforts, Medicare spending control, provider administrative burden, and access-to‑care dynamics.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill contains two functional elements: a short title and a single operative prohibition. It names the Act and then declares that the Secretary of HHS shall not implement the WISeR model as described in the specified Federal Register notice, nor any substantially similar model, under the Medicare program.
The WISeR notice’s title makes clear that the model relies on prior authorization for select services to reduce wasteful or inappropriate care; the statute therefore targets that class of utilization management activity.
Because the text reaches both the specific WISeR notice and ‘‘substantially similar’’ models, the ban is broader than a targeted repudiation of a single pilot design. That breadth creates immediate interpretive work for CMS: the agency must decide which activities would be captured as ‘‘substantially similar’’ and which program integrity or demonstration tools remain available.
Practically, CMS could respond by redesigning programs to avoid the statutory language, by pausing related initiatives, or by litigating the statute’s scope if it believes the ban conflicts with other statutory authorities.Operationally, the bill does not amend the Social Security Act or change Medicare benefit definitions; it is a direct statutory prohibition on agency action. It contains no transition period, no exceptions for urgent anti‑fraud deployments, and no supplemental funding for alternative program integrity efforts.
The result is a blunt constraint on one approach to managing utilization that leaves open both regulatory workarounds and legal ambiguity about what constitutes a ‘‘substantially similar’’ model.
The Five Things You Need to Know
The bill directs that the HHS Secretary shall not implement the WISeR model described in 90 Fed. Reg. 28749 (July 1, 2025).
The prohibition explicitly covers ‘‘any substantially similar model,’’ extending the ban beyond the single Federal Register notice.
The ban applies specifically to implementation ‘‘under the Medicare program,’’ targeting CMS’s authority to deploy the model.
The statute is a single substantive section with no exceptions, transition timeline, or enforcement mechanism besides the statutory prohibition itself.
The bill does not amend underlying Medicare statute language (e.g.
the Social Security Act); it operates as a stand‑alone prohibition on agency implementation rather than a change to benefit or coverage rules.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This section supplies the Act’s formal names — the ‘‘Seniors Deserve Streamlined Medical Approvals for Timely, Efficient Recovery Care Act of 2025’’ and the shorter ‘‘Seniors Deserve SMARTER Care Act of 2025.’’ It has no operational effect on policy but frames congressional intent and branding for the measure.
Prohibition on implementing the WISeR model
This is the operative provision: it instructs the HHS Secretary not to implement the innovative payment and service‑delivery model set out in the WISeR Federal Register notice, and it extends that prohibition to ‘‘substantially similar’’ models. Mechanically, this is a statutory bar on agency action — not a definition or a funding change. That means CMS loses the specific experimental route described in the notice unless it redesigns an approach that courts or Congress would not find ‘‘substantially similar.’’ The provision’s lack of definitions (for ‘‘implement’’ or ‘‘substantially similar’’) makes its scope uncertain and gives rise to administrative and legal disputes over what alternative models remain lawful.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Providers and clinician groups that opposed WISeR — the ban removes a targeted prior‑authorization process that would have required them to obtain approvals before furnishing certain services, reducing immediate administrative burden and risk of service denials.
- Medicare beneficiaries who worry about care delays from prior authorization — the prohibition preserves current access pathways for services that would have been subject to WISeR prior authorization, at least in the short term.
- Trade associations and suppliers of services targeted as potentially wasteful — those entities avoid decreased utilization that a successful WISeR pilot might have triggered.
Who Bears the Cost
- CMS and HHS — the law removes a tool CMS was preparing to test for managing potentially low‑value services, forcing the agency to seek alternative program‑integrity strategies or accept higher projected utilization. That could complicate budget and operational planning.
- Taxpayers and the Medicare Trust Fund — if WISeR would have reduced inappropriate spending, the statutory ban could leave potential savings unrealized, increasing long‑term program costs.
- Vendors of prior‑authorization technology and third‑party administrators — these companies lose a prospective federal deployment and market opportunity tied to a high‑profile CMS model.
Key Issues
The Core Tension
The core dilemma is between program integrity and access/administrative burden: Congress can eliminate a prior‑authorization tool to protect beneficiaries from delays and providers from paperwork, but doing so limits CMS’s ability to curb wasteful or inappropriate services—a trade‑off with real budgetary and care‑quality consequences and no obvious, risk‑free middle ground.
The bill’s brevity is also its primary policy complication. It forbids ‘‘implementation’’ but does not define the term; CMS may interpret that narrowly (blocking only direct deployment of the model as written) or broadly (precluding any substantially similar prior‑authorization mechanism).
The undefined ‘‘substantially similar’’ phrase invites administrative churn: CMS could attempt to redesign a model that achieves similar objectives but uses different mechanics, prompting litigation over whether the redesign crosses the statutory line.
A second tension is practical: prior authorization can both curb inappropriate care and create access delays and added provider paperwork. The statute chooses one side of that trade‑off by eliminating a potential control lever, but it provides no substitute mechanism to address wasteful care or fraud.
That raises follow‑on questions about how CMS will pursue program integrity, whether Congress will fund alternative approaches, and how beneficiaries and providers will fare as utilization patterns evolve.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.